Dear Colleagues,

I hereby invite you to submit manuscripts on CAR-T cell therapy.

CAR (chimeric antigen receptor) T cell therapy is a novel type of cellular therapy that has shown highly promising results for the treatment of hematological cancers and of other cancer types. The chimeric antigen receptor construct involves signaling peptide, single chain variable fragment (scFv) of antibody that binds to tumor antigen, hinge, different co-stimulatory domains and activation CD3 domains. Once CAR-T cells bind to tumor antigen, the T cell becomes activated leading to killing of tumor cell due to the activation of intracellular signaling and the secretion of cytokines. However, there are still many challenges for this novel therapy, such as its efficacy in solid cancers, overcoming the repressive tumor microenvironment, checkpoint pathways and on-target-off-tumor activity. This issue will focus on CAR design, CAR intracellular signaling, and various ways to improve this therapy such as combination with other immune and anti-cancer cell therapies. It will also highlight novel approaches for CAR-T cell therapy, focus on CAR-T cell therapy against different types of cancer, discuss challenges and present new clinical advances and perspectives in this field.

Dr. Vita Golubovskaya

Guest Editor